Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review

Oronzo Brunetti; Angela Calabrese; Loredana Palermo; Antonio Giovanni Solimando; Antonella Argentiero

doi:10.1002/ccr3.2496

Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review

Oronzo Brunetti, Angela Calabrese, Loredana Palermo, Antonio Giovanni Solimando, Antonella Argentiero

IRCCS Giovanni Paolo II

Research output: Contribution to journal › Article › peer-review

Abstract

Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.

Original language	English
Pages (from-to)	2379-2383
Number of pages	5
Journal	Clinical Case Reports
Volume	7
Issue number	12
DOIs	https://doi.org/10.1002/ccr3.2496
Publication status	Published - Dec 1 2019

Keywords

colorectal cancer
long-term survival
regorafenib

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1002/ccr3.2496

Fingerprint Dive into the research topics of 'Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review'. Together they form a unique fingerprint.

Cite this

@article{082fc6b8fd714a07a9ed659e8d847f3c,

title = "Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review",

abstract = "Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.",

keywords = "colorectal cancer, long-term survival, regorafenib",

author = "Oronzo Brunetti and Angela Calabrese and Loredana Palermo and Solimando, {Antonio Giovanni} and Antonella Argentiero",

year = "2019",

month = dec,

day = "1",

doi = "10.1002/ccr3.2496",

language = "English",

volume = "7",

pages = "2379--2383",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "John Wiley and Sons Ltd",

number = "12",

}

TY - JOUR

T1 - Long-term survival of an advanced colorectal cancer patient treated with Regorafenib

T2 - Case report and literature review

AU - Brunetti, Oronzo

AU - Calabrese, Angela

AU - Palermo, Loredana

AU - Solimando, Antonio Giovanni

AU - Argentiero, Antonella

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.

AB - Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.

KW - colorectal cancer

KW - long-term survival

KW - regorafenib

UR - http://www.scopus.com/inward/record.url?scp=85074556936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074556936&partnerID=8YFLogxK

U2 - 10.1002/ccr3.2496

DO - 10.1002/ccr3.2496

M3 - Article

AN - SCOPUS:85074556936

VL - 7

SP - 2379

EP - 2383

JO - Clinical Case Reports

JF - Clinical Case Reports

SN - 2050-0904

IS - 12

ER -